^
    Back
    Association details:
    Biomarker:TERT mutation
    Cancer:Hepatocellular Cancer
    Drug:Avastin (bevacizumab) (VEGF-A inhibitor) +
    Tecentriq (atezolizumab) (PD-L1 inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    New
    Source:
    Cancers (Basel)
    Title:

    Circulating Cell-Free DNA Profiling Predicts the Therapeutic Outcome in Advanced Hepatocellular Carcinoma Patients Treated with Combination Immunotherapy

    Published date:
    07/11/2022
    Excerpt:
    We enrolled a multicenter cohort of 85 HCC patients treated with atezolizumab and bevacizumab (Atezo/Bev) between 2020 and 2021….Twenty-six patients with a TERT mutation had significantly shorter OS than those without.
    DOI:
    10.3390/cancers14143367